The general public often assumes that medical products will be
available to members of the U.S. armed forces in harm's way.
Availability of safe and effective drugs and vaccines, however, is
never an accident; such products are the fruition of focused and
methodical research, testing and evaluation over many years.
Medical research is inherently a high risk endeavor, and even the
most efficient programs can span almost 15 years and cost over $1
billion from product discovery to Food and Drug Administration
licensure. In this monograph, Colonel Coleen Martinez examines the
productivity of the Department of Defense's biodefense research
program over the course of more than 35 years, coupled with changes
in the global research environment since the events of September
11, 2001. Few will argue the need for a national investment in
biodefense. Where the deployment of a biologic agent of mass
destruction is largely an unpredictable risk, the outcome certainly
could be catastrophic for an unprotected population.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!